Table 2.
Anti-tumor necrosis factor alpha therapy for management of refractory inflammatory bowel disease after liver transplantation
| Author | Number LT patients | Clinical outcome | Endoscopic outcome | Adverse events |
| Sandhu et al[13] | 6 | Response: 67% | - | Systemic lupus erythematosus |
| Colorectal cancer | ||||
| Mohabbat et al[14] | 8 | Response: 87.5% | Mucosal healing: 42.9% | Oral candidiasis |
| Clostridium difficile colitis | ||||
| Bacterial pmeumonia | ||||
| Cryptosporidiosis | ||||
| Post-tansplant lympho-proliferative disorder | ||||
| Lal et al[15] | 1 | Response: 100% | Improvement: 100% | No |
| El-Nachef et al[16] | 2 | Response: 100% | - | No |
| Indriolo et al[18] | 4 | Response: 75% | Mucosal healing: 33% | Molluscum contagiosum |